/
Immunology
Systemic Sclerosis
47
Pipeline Programs↗
47
Active Trials↗
54
Companies Involved↗
Systemic Sclerosis is a moderately active landscape with 47 programs across 54 companies. The most active players are Amgen, Topadur Pharma AG, AstraZeneca. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical15
Phase 16
Phase 219
Phase 37
Approved
No programs
Analysis
Modality Breakdown
64%
Small molecule
25 of 39 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 39 classified programs, each share of the total. Modality classified for 96% of 47 pipeline programs.
Analysis
Trial Status
173
clinical trials
Completed77 · 45%
Recruiting27 · 16%
Terminated21 · 12%
Not yet recruiting16 · 9%
Unknown status15 · 9%
Withdrawn9 · 5%
Other8 · 5%
Clinical Trials
Trial Activity
173 trials
Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)
Recruiting·—·Phase 2·NCT03630211·8 enrolled
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06375005·38 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)